MedTrace Logo

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

NCT01474681 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2020-12-30

Study results available
· View outcomes & findings →

Summary

This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.

Conditions

Interventions

BIOLOGICAL

HSC835

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-09
Primary Completion
2016-10-03
Completion
2016-10-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01474681 on ClinicalTrials.gov